VELARU GALACTIC EXHIBIT PACK — PHARMA / CLINICAL TRIALS
Jurisdiction: Canada (ca)
Modality: Text / Chat
Program: Velaru Pharma / Clinical Trials · Canada (galactic_pharma_ca)
Product ID: pharma:ca:bundle:text
Vertical: pharma
Generated: 2026-08-15T10:18:17.117241Z
Authority: Canada OSFI E-23 Pack — 21 CFR Part 11 Clinical AI Audit Pack
Deadline: AIDA (pending) + OSFI E-23 model risk
Velaru verify: https://velaru.onrender.com/verify

EXHIBIT A — AI INVENTORY
[
  {
    "named_entity": "Velari",
    "slug": "velari",
    "ai_use_case": "AI-assisted Pharma / Clinical Trials decisions",
    "vertical": "pharma",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/4c58eac890bfd031ce2189de5a1ca9ea292a0c837f5f535daf164aef34f31e53",
    "compliance_state": "grace_period",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.onrender.com/bundle/pre-dispute/d8fb129c0c0c78d05256/export.txt",
    "diligence_url": "https://velaru.onrender.com/diligence/velari"
  },
  {
    "named_entity": "LinkAudit Test",
    "slug": "linkaudit-test",
    "ai_use_case": "AI-assisted Pharma / Clinical Trials decisions",
    "vertical": "pharma",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/58ddedd1974156453bc55daef6a9857d8570d56388becbb2a80bf5bac76b771b",
    "compliance_state": "grace_period",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.onrender.com/bundle/pre-dispute/78aa6e3f3a84cf1a88c0/export.txt",
    "diligence_url": "https://velaru.onrender.com/diligence/linkaudit-test"
  },
  {
    "named_entity": "Link Audit Co",
    "slug": "link-audit-co",
    "ai_use_case": "AI-assisted Pharma / Clinical Trials decisions",
    "vertical": "pharma",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/d00533b7b6c0495802b4250abd5c29f60bd9f2ad3fb141bba2d9a5afee5f5542",
    "compliance_state": "grace_period",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.onrender.com/bundle/pre-dispute/fea572f3996c4b963779/export.txt",
    "diligence_url": "https://velaru.onrender.com/diligence/link-audit-co"
  }
]

EXHIBIT B — GOVERNANCE FRAMEWORK
{
  "framework": "Velaru Mandate Registry \u2014 Pharma / Clinical Trials",
  "exhibit_authority": "Canada OSFI E-23 Pack \u2014 21 CFR Part 11 Clinical AI Audit Pack",
  "regulatory_frameworks": [
    "FDA 21 CFR Part 11",
    "GCP ICH E6",
    "EU AI Act Annex III",
    "AIDA proposal",
    "OSFI E-23",
    "PIPEDA",
    "Quebec Law 25"
  ],
  "standards_alignment": [
    "POSS-2",
    "DRP-1",
    "TCB",
    "FRE 707 pre-compliance",
    "ISO 42001"
  ],
  "human_oversight": "release clinical batch / report adverse event",
  "third_party_verification": "https://velaru.onrender.com/verify (operator-independent)",
  "data_lineage": "Hash-chained Ed25519 receipts; optional RFC3161 + external anchor",
  "mirror_trap": "Sponsors using vendor AI for protocol deviation detection \u2014 sponsor owns FDA finding, vendor owns nothing. \u00b7 Quebec Law 25 already strict on automated decisions \u2014 ROC catching up with AIDA.",
  "chain_integrity": {
    "depth": 340,
    "invariant_holds": true
  }
}

EXHIBIT D — DATA INPUTS & VALIDATION
{
  "data_validation_method": "Cryptographic receipt per AI decision; public verify without trusting deployer, vendor, or Velaru operator",
  "bias_testing_proxy": "Asymmetry score from live chain signals",
  "model_change_control": "Policy lock registry \u2014 criteria hash frozen pre-dispute",
  "logging_retention": "90-day pre-dispute window minimum; permanent verify permalinks",
  "external_validator": "Nisaba LLC / Velaru",
  "validator_independence": "Client-side Ed25519 verify; BYOK tri-receipt optional",
  "headline_stat": "21 CFR Part 11 already requires what Velaru does \u2014 not AI safety, compliance",
  "global_leaders_addressed": [
    "FDA",
    "Pfizer",
    "IQVIA",
    "Veeva",
    "EMA",
    "OSFI",
    "RBC",
    "OPC"
  ]
}

MIRROR TRAP (regulatory insight)
Sponsors using vendor AI for protocol deviation detection — sponsor owns FDA finding, vendor owns nothing. · Quebec Law 25 already strict on automated decisions — ROC catching up with AIDA.

NERVE CARDS — WHY GLOBAL LEADERS CARE
[
  {
    "title": "483 observations",
    "body": "FDA inspection: show audit trail for AI-flagged deviation \u2014 altered records = criminal referral pattern.",
    "source": "vertical"
  },
  {
    "title": "ICH E6 GCP",
    "body": "AI-assisted monitoring must be in validation documentation \u2014 post-hoc PowerPoint fails.",
    "source": "vertical"
  },
  {
    "title": "Trial insurance",
    "body": "Clinical trial insurers now ask AI governance questionnaire \u2014 receipts beat questionnaires.",
    "source": "vertical"
  },
  {
    "title": "[Canada] OSFI banks",
    "body": "Canadian bank AI \u2014 E-23 model risk parallels SR 11-7.",
    "source": "jurisdiction"
  },
  {
    "title": "[Canada] Bill C-27",
    "body": "AIDA when passed \u2014 early receipt infrastructure = compliance head start.",
    "source": "jurisdiction"
  },
  {
    "title": "[Text / Chat] Modality hook",
    "body": "Baseline \u2014 all frameworks apply to text decisions.",
    "source": "modality"
  }
]

BOOK SUMMARY: {
  "total_insureds": 3,
  "compliant": 0,
  "grace_period": 3,
  "non_compliant": 0,
  "expired": 0,
  "not_enrolled": 0,
  "compliant_pct": 0.0
}

TAM / EXPOSURE: $200B+ pharma R&D · AI in trial design exploding
INSURANCE LINES: Product liability, Clinical trial E&O

DISCLAIMER: External validation evidence pack — not legal advice, not filed rate approval.